ClinicalTrials.Veeva

Menu
B

Be Well Medical Center | Berkley, MI

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Emtricitabine
Lenacapavir
Tenofovir Alafenamide
Tenofovir Disoproxil Fumarate
TDF
Rilpivirine
Bictegravir
TAF
Ritonavir
Elvitegravir

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

7 of 42 total trials

A Clinical Trial of STP0404 in Adults With HIV-1 Infection

The purpose of this study is to evaluate the antiviral effect, safety, tolerability, and pharmacokinetics of STP0404 in adult participants living wit...

Enrolling
HIV-1-infection
Drug: High-dose STP0404 (Pirmitegravir)
Drug: Low-dose STP0404 (Pirmitegravir)

The goal of this study is to test the effectiveness, safety, and tolerability of the combination of broadly neutralizing antibodies (bNAbs) (teropavi...

Active, not recruiting
HIV Infections
Drug: Lenacapavir Tablet
Drug: Zinlirvimab

This is a randomized, active-controlled, double-blind clinical study designed to evaluate the antiretroviral activity, safety, and tolerability of do...

Enrolling
HIV-1 Infection
Drug: BIC/FTC/TAF
Drug: Placebo to DOR/ISL

The primary objective of this study is to evaluate the efficacy of oral weekly islatravir (ISL) in combination with lenacapavir (LEN) in virologicall...

Active, not recruiting
HIV-1 Infection
Drug: B/F/TAF
Drug: ISL

The goal of this clinical study is to test how well the study drug, lenacapavir (LEN), works in preventing the risk of HIV.

Active, not recruiting
Pre-Exposure Prophylaxis of HIV Infection
Drug: PTM F/TDF
Drug: Placebo SC LEN

The goal of this clinical study is to learn more about the effects of switching to the study drugs, bictegravir (BIC) plus lenacapavir (LEN), versus...

Enrolling
HIV-1-infection
Drug: Stable Baseline Regimen
Drug: Bictegravir

The primary objective of this study is to evaluate the antiviral activity of lenacapavir (formerly GS-6207) administered as an add-on to a failing re...

Active, not recruiting
HIV-1-infection
Drug: Optimized Background Regimen (OBR)
Drug: Failing ARV Regimen

Trial sponsors

Gilead Sciences logo
AbbVie logo
Bristol-Myers Squibb (BMS) logo
Merck Sharp & Dohme (MSD) logo
R
S

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems